Interferon alpha for chronic Hepatitis D by Abbas, Zaigham et al.
eCommons@AKU
Department of Medicine Department of Medicine
December 2011
Interferon alpha for chronic Hepatitis D
Zaigham Abbas
Agha Khan University, zaigham.abbas@aku.edu
Muhammad Arsalan Khan
Mohammad Salih
Aga Khan University
Wasim Jafri
Aga Khan University, wasim.jafri@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med
Part of the Gastroenterology Commons, Oncology Commons, and the Virus Diseases Commons
Recommended Citation
Abbas, Z., Khan, M., Salih, M., Jafri, W. (2011). Interferon alpha for chronic Hepatitis D. Cochrane Database of Systematic Reviews(12),
6002-6002.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_med/61
Cochrane Database of Systematic Reviews
Interferon alpha for chronic hepatitis D (Review)
Abbas Z, Khan MA, Salih M, Jafri W
Abbas Z, KhanMA, Salih M, Jafri W.
Interferon alpha for chronic hepatitis D.
Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No.: CD006002.
DOI: 10.1002/14651858.CD006002.pub2.
www.cochranelibrary.com
Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
12DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Mortality, Outcome 1 Interferon alpha versus no intervention. . . . . . . . . . 29
Analysis 2.1. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 1 Failure of virological
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Analysis 2.2. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 2 Failure of virological
response: six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . . 31
Analysis 2.3. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 3 Failure of biochemical
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Analysis 2.4. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 4 Failure of biochemical
response: six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . . 33
Analysis 2.5. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 5 Failure of histological
response. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 3.1. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 1 Failure of virological response:
end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Analysis 3.2. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 2 Failure of virological response:
six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . . . . . 35
Analysis 3.3. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 3 Failure of biochemical
response: end of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 3.4. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 4 Failure of biochemical
response: Six months after completion of treatment. . . . . . . . . . . . . . . . . . . . . 37
37ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
41INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interferon alpha for chronic hepatitis D
Zaigham Abbas1 , Muhammad Arsalan Khan2, Mohammad Salih3, Wasim Jafri3
1Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. 2Department of Hepa-
tobiliary Surgery, Sindh Institute of Urology and Transplantation, Karachi, Pakistan. 3Department of Medicine, Aga Khan University
Hospital, Karachi, Pakistan
Contact address: Zaigham Abbas, Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Diwan
Complex, Chand Bibi Road, Karachi, Sindh, Pakistan. drzabbas@gmail.com.
Editorial group: Cochrane Hepato-Biliary Group.
Publication status and date: New, published in Issue 12, 2011.
Citation: Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database of Systematic Reviews
2011, Issue 12. Art. No.: CD006002. DOI: 10.1002/14651858.CD006002.pub2.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Hepatitis D virus is a small defective RNA virus that requires the presence of hepatitis B virus infection to infect a person. Hepatitis D
is a difficult-to-treat infection. Several clinical trials have been published on the efficacy of interferon alpha for hepatitis D virus (HDV)
infection. However, there are few randomised trials evaluating the effects of interferon alpha, and it is difficult to judge any benefit of
this intervention from the individual trials.
Objectives
To evaluate the beneficial and harmful effects of interferon alpha for patients with chronic hepatitis D.
Search methods
We identified relevant for the review randomised clinical trials by electronic searches in the Cochrane Hepato-Biliary Group Controlled
Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE,
and Science Citation Index Expanded until May 2011. We also checked the bibliographic references of identified randomised trials,
textbooks, and review articles in order to find randomised trials not identified by the electronic searches.
Selection criteria
Randomised clinical trials evaluating interferon alpha versus placebo or no intervention for patients with chronic hepatitis D infection.
Data collection and analysis
Two authors assessed the trials and extracted data on mortality, virologic, biochemical, and histological response as well as adverse
events at end of treatment and six months or more after completing treatment. The analyses were performed using the intention-
to-treat principle including all randomised participants irrespective of follow-up. Drop-outs, withdrawals, and non-compliance were
considered as treatment failures. Data were analysed with fixed- and random-effects models. Reported results were based on fixed-effect
model except in cases where statistical significance varied between the two models.
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Main results
Six randomised trials fulfilled the inclusion criteria. Two hundred and one randomised participants (male = 174) were included. The
risk of bias in all the included trials was high. Five trials compared interferon alpha with no treatment in the control group. One of these
trials had two treatment arms with a higher dose and lower dose of interferon alpha and a no-treatment control group. We analysed
both treatment regimens as a single group in a primary analysis and as separate groups in the subgroup analysis of different interferon
dosages. The sixth trial compared only a higher dose of interferon alpha with a lower dose.
Meta-analysis of five trials comparing interferon alpha with no-treatment control group included 169 participants. There were seven
drop-outs in the treatment group and nine in the control group. One patient out of 92 (1.1%) died in the interferon alpha group
compared with zero out of 77 (0.0%) in the no-intervention control group (risk ratio (RR)) 3.00; 95% confidence interval (CI) 0.14
to 66.5). Interferon alpha led to failure of end of treatment virological response in 62/92 (67.4%) of the patients compared with 71/
77 (92.2%) in the untreated controls (RR 0.76, 95% CI 0.66 to 0.87, P = 0.0001 by fixed-effect model and RR 0.71, 95% CI 0.43 to
1.16, P = 0.17 by random-effects model). Failure of normalisation of alanine aminotransferase (ALT) at the end of treatment was seen
in 60/92 (65.2%) patients treated with interferon alpha versus 76/77 (98.7%) in the control group (RR 0.69, 95% CI 0.59 to 0.80, P
< 0.00001). Sustained virological response was not achieved in 76/92 (82.6%) of patients on interferon compared with 73/77 (94.8%)
of controls (RR 0.89, 95% CI 0.80 to 0.98, P = 0.02). Serum alanine aminotransferase was abnormal in 81/92 (88.0%) treated with
interferon alpha patients at six months post-treatment follow-up compared with 76/77 (98.7%) in controls (RR 0.92, 95% CI 0.84 to
0.99, P = 0.04). There was no significant histological improvement in 67/92 (72.8%) patients treated with interferon alpha compared
with 65/77 (84.4%) in controls (RR 0.86, 95% CI 0.74 to 1.00, P = 0.06).
Two trials comparing a higher dose of interferon alpha with the lower dose showed no significant difference in sustained virological
response (76.7% compared with 90.0%) (RR 0.85, 95% CI 0.68 to 1.07, P = 0.16). Adverse events such as flu-like symptoms, asthenia,
weight loss, alopecia, thrombocytopenia, and leukopenia were reported in all these trials and the adverse events were related to interferon
alpha. These were common and sometimes severe. One patient in the treatment group was reported to have died by suicide towards
the end of the study period.
Authors’ conclusions
Interferon alpha does not seem to cure hepatitis D in most patients. The agent seems effective in suppressing viral and liver disease
activity in some patients, but this improvement is not sustained in themajority of patients. We cannot exclude overestimation of benefits
and underestimation of harms due to high risk of bias (systematic errors) and high risk play of chance (random errors). Therefore, more
randomised trials with large sample sizes and less risk of bias are needed before interferon can be recommended or refuted.
P L A I N L A N G U A G E S U M M A R Y
Interferon alpha for patients with chronic hepatitis D
Hepatitis D virus is unique in that it can only infect a person who is already infected by hepatitis B virus. Chronic hepatitis D is a
difficult-to-treat infection. Several antiviral and immunomodulating agents have been evaluated in treatment of hepatitis D. However,
with the exception of interferon, all of them proved ineffective. This meta analysis of six randomised clinical trials of interferon shows
that even Interferon alpha is not an ideal drug for this infection. Among the 169 participants included in primary meta analysis,
interferon alpha induced loss of virus, normalisation of liver tests, and improvement in the liver biopsy in more patients compared
with those who were left untreated. Unfortunately, most of these patients did not have sustained response after stopping treatment.
Additional analysis of two trials comparing a higher dose of interferon alpha with lower dose among randomly assigned participants
showed no significant difference in outcome between the two groups. There were differences in dosage and duration of interferon alpha
used among included trials as well as some other methodological weakness which places a high risk of bias in this meta analysis.
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B A C K G R O U N D
Hepatitis D virus (or delta virus) (HDV) is a defective small sin-
gle-stranded circular RNA virus that requires the helper function
of hepatitis B virus (HBV) for viral assembly and propagation
(Rizzetto 1977). Acute infection with HDV acquired by coinfec-
tion with HBV is often severe. However, most patients achieve
usually a complete recovery and only 2% of the patients progress
to chronicity (Farci 2003). Superinfection of HDV in persons
with HBV infection leads to progressive disease and cirrhosis in
approximately 80% of patients (Rizzetto 2003). Cirrhosis devel-
ops earlier in HDV-infected patients than patients infected only
with chronic HBV (Rizzetto 1983; Hughes 2011). Up to 5% of
the world’s population is infected with HBV, and probably 5%
of the HBV carriers have HDV superinfection (Gaeta 2001). Ac-
cordingly, about 15 million people may have chronic hepatitis D
infection.
HDV is difficult to eradicate as most of the possible therapeutic
targets are normal cellular proteins. The sole enzymatic activity
that HDV possesses is a ribozyme that autocleaves the circular
RNA, producing a linear molecule (Sharmeen 1988). Concomi-
tant infection with an RNA (HDV) and a DNA (HBV) virus
makes chronic hepatitis Dmore difficult to treat than chronic hep-
atitis B alone. Aswith hepatitis B, poor results were obtained in the
treatment of hepatitis D with immunosuppressive and immunos-
timulant drugs (Arrigoni 1983; Rizzetto 1983). The mechanism
of action of interferon in chronic hepatitis D is poorly understood.
InHDV transfected hepatoma cell lines, HDV replication was not
affected by interferon (Ottobrelli 1991; Ilan 1992). In vitro exper-
iments apparently contrast with the results observed in patients, in
whom response to interferon is often characterised by a concomi-
tant reduction in HDV viraemia and in alanine aminotransferase
(ALT) levels, suggesting a direct antiviral effect of interferon on
HDV.
Several clinical trials on the long-term administration of inter-
feronwere undertaken in the late 1980s (Farci 1994;Malaguarnera
1996). The response, assessed by the normalisation of serum ala-
nine aminotransferase (ALT) levels and clearance of serum HDV
RNA varied widely. Moreover, it occurred at different times from
the beginning of treatment, sometimes even after discontinuation
of interferon. The proportion of patients with response and relapse
seemed proportional to the dose of interferon (Di Bisceglie 1990;
Madejon 1994). Sustained responses were unusual and often in-
complete, showing persistently normal ALT despite the recrudes-
cence of HDV viraemia. Concomitant sustained biochemical and
virological responses were usually accompanied by the clearance
of serum hepatis B surface antigen (HBsAg) and seroconversion
to anti-HBs antibody (Battegay 1994).
Farci et al demonstrated that interferon alpha, given in a dose of 9
million units three times a week for 48 weeks, was generally well
tolerated and resulted in clearance of serum HDV RNA, normal
ALT values, and histologic improvement in 50% of patients with
chronic hepatitisD (Farci 1994). A complete biochemical response
persisted for up to four years in half the patients who had normal
ALT values at the end of therapy, whereas the effects on viral
replication were not sustained in these patients. Niro et al reviewed
the trials on the treatment of hepatitis D and concluded that the
medical treatment of chronic hepatitis D rested on interferon,
which should be administered at high doses (9 to 10 million units
three times a week) to patients with compensated liver disease
and as soon as chronic HDV disease was diagnosed (Niro 2005).
Treatment should be prolonged for 12 months as response, ie,
clearance of HDV RNA and normalisation of ALT levels, can be
delayed and sometimes occur after the end of the treatment.
There is one previous meta-analysis available dealing with inter-
feron alpha for hepatitis D (Hadziyannis 1991). It is based on re-
duction in ALT levels as the primary outcome measure. We could
not find any comprehensive meta-analyses that evaluated inter-
feron alpha for chronic hepatitis D in terms of mortality and viro-
logical, biochemical, and histological responses at the end of treat-
ment and the end of the follow-up. Therefore, we felt the need to
perform the present Cochrane systematic review.
O B J E C T I V E S
To evaluate the beneficial and harmful effects of interferon alpha
in the treatment of patients with chronic hepatitis D infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of language, publication
date, or blinding.
Types of participants
Inclusion criteria
Included in this analysis were patients with chronic hepatitis D
infection. That is, patients with detectable serum HDV RNA for
at least six months with inactive or active HBV carrier state, and
active inflammatory disease, ie, persistent or intermittent raised ac-
tivities of alanine aminotransferase (ALT) and/or aspartate amino-
transferase (AST) above the upper limit of normal values (Farci
1994). Patients with compensated delta virus related cirrhosis were
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included as well. Patients with hepatitis C virus and HIV co-in-
fection, alcoholism, patients using immunosuppressive drugs, and
liver transplanted patients were also considered for inclusion in
subgroup analyses.
Exclusion criteria
Patients with acute hepatitis D (ie, acute co-infection with HDV
and HBV or acute HDV superinfection on HVB).
Types of interventions
Standard interferon alpha or pegylated interferon alpha versus
placeboor no intervention. Interferon alpha could be administered
in any dosage via the subcutaneous or intramuscular route. We
considered for inclusion also trials with co-interventions if these
were administered equally to the relevant intervention groups.
Types of outcome measures
Primary outcomes
1. Mortality.
2. Failure of sustained virologic response: number of patients with
positive HDV RNA at six months or more after treatment.
3. Adverse events: any unfavourable or unintended sign (including
an abnormal laboratory finding), symptom, or disease (new or ex-
acerbated) associated with use of a medicinal product (ICH-GCP
1997). These include serious or minor; expected or unexpected;
and study-related, possibly study-related, or not study-related
events.This also included patients developing decompensation
during interferon therapy.
4. Quality of life.
Secondary outcomes
1. Failure of sustained biochemical response: failure of normalisa-
tion of ALT and/or AST levels at six months or more after treat-
ment.
2. Failure of histological response: failure of improvement of in-
flammatory activity as assessed by liver biopsy.
Search methods for identification of studies
Electronic searches
Relevant randomised clinical trials were identified by electronic
searches in the Cochrane Hepato-Biliary Group Controlled Trials
Register (Gluud 2011), the Cochrane Central Register of Con-
trolled Trials (CENTRAL) in The Cochrane Library, MEDLINE,
EMBASE, and Science Citation Index Expanded (Royle 2003).
Last date of search was May 31, 2011. Search strategies applied
to the individual electronic databases with the time span of the
searches are given in Appendix 1.
Searching other resources
We also checked the bibliographic references of identified ran-
domised trials, textbooks, and review articles in order to find ran-
domised trials not identified by the electronic searches.
Data collection and analysis
Selection of studies
We retrieved the full paper articles for assessment, and review
authors applied the inclusion criteria to the trials of interest to the
review independently of each other. There were no disagreements
among the authors.
Data extraction and management
Two authors (ZAB andMAK) extracted the following prespecified
characteristics of all included randomised clinical trials indepen-
dently. In case of discrepancy, the opinion of the third reviewer
(WJA or MSA) was sought in order to reach consensus. Data in-
cluded:
• Participants: age, sex, ethnic origin, form(s) of transmission,
previous antiviral treatment, presence of cirrhosis at entry,
criteria used to classify chronic hepatitis D, number of patients
randomised, reasons for withdrawal from the trial.
• Interventions: dosage and duration of therapy, and method
of administration, intervention in the control group, and any co-
interventions.
• Outcomes: as listed above under outcome measures.
Assessment of risk of bias in included studies
The methodological quality of a trial can affect the estimate of
intervention efficacy (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008; Gluud 2011). Risk of bias of the randomised clinical
trials was assessed using the definitions of following domains (
Higgins 2011).
Sequence generation
- Low risk of bias: sequence generation was achieved using com-
puter random number generation or a random number table.
Drawing lots, tossing a coin, shuffling cards, and throwing dice
are also adequate if performed by an independent adjudicator.
- Uncertain risk of bias: the trial is described as randomised but
the method of sequence generation was not specified.
- High risk of bias: the sequence generation method is not, or
may not be, random.Quasi-randomised studies, those using dates,
names, or admittance numbers in order to allocate patients are
inadequate and were excluded for the assessment of benefits but
not for the assessment of harms.
Allocation concealment
- Low risk of bias: allocation was controlled by a central and in-
dependent randomisation unit, serially numbered, opaque and
4Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sealed envelopes, or similar, so that intervention allocations could
not have been foreseen in advance of, or during, enrolment.
- Uncertain risk of bias: the trial was described as randomised but
the method used to conceal the allocation was not described, so
that intervention allocations may have been foreseen in advance
of, or during, enrolment.
- High risk of bias: if the allocation sequence was known to the
investigators who assigned participants or if the study was quasi-
randomised. Quasi-randomised studies were excluded for the as-
sessment of benefits but not for the assessment of harms.
Blinding
- Low risk of bias: the trial was described as blinded, the parties
that were blinded, and the method of blinding was described, so
that knowledge of allocation was adequately prevented during the
trial.
- Uncertain risk of bias: the trial was described as blind, but the
method of blinding was not described, so that knowledge of allo-
cation was possible during the trial.
- High risk of bias: the trial was not blinded, so that the allocation
was known during the trial.
Incomplete outcome data
- Low risk of bias: the numbers and reasons for dropouts and
withdrawals in all intervention groups were described or if it was
specified that there were no dropouts or withdrawals.
- Uncertain risk of bias: the report gave the impression that there
had been no dropouts or withdrawals, but this was not specifically
stated.
- High risk of bias: the number or reasons for dropouts and with-
drawals were not described.
Selective outcome reporting
- Low risk of bias: pre-defined, or clinically relevant and reasonably
expected outcomes are reported on.
- Uncertain risk of bias: not all pre-defined, or clinically relevant
and reasonably expected outcomes are reported on or are not re-
ported fully, or it is unclear whether data on these outcomes were
recorded or not.
- High risk of bias: one or more clinically relevant and reasonably
expected outcomes were not reported on; data on these outcomes
were likely to have been recorded.
If a trial obtained the judgement ’low risk of bias’ in all the six
bias risk domains, then it was categorised as a trial with low risk
of bias for the purpose of data analyses. In all other cases, the trial
was categorised as a trial with high risk of bias.
Dealing with missing data
An intention-to-treat analysis included all randomised partici-
pants. Any missing observations were assumed to have a poor out-
come.
Assessment of heterogeneity
ReviewManager software (RevMan) was used for the data analysis
(Deeks 2011; RevMan 2011). Continuous outcomes are expressed
as mean differences (MD) with 95% confidence intervals (CI).
For dichotomous variables we calculated relative risk with 95%
CI. Intention-to-treat principle was applied everywhere.
Heterogeneity between trials was explored by considering the bias
risk of trials, clinical setting, and patients involved. Chi-squared
test for heterogeneity was used to provide an indication of be-
tween trials heterogeneity. In addition, the degree of heterogeneity
observed in the results was quantified using the I-squared statis-
tic (Higgins 2003). The heterogeneity statistic I2, interpreted as
“the percentage of variability due to heterogeneity between studies
rather than sampling error depends on precision, that is, the size
of the studies included” (Rücker 2008).
Assessment of reporting biases
Regression asymmetry test to assess funnel plot asymmetry was
to be employed to indicate the presence of bias (Egger 1997).
However, we did not identify a sufficient number of trials in order
to draw it.
Data synthesis
We analysed the data with both fixed-effect (DeMets 1987) and
random-effects (DerSimonian 1986)model meta-analyses. In case
there was no difference in statistical significance between the re-
sults obtained with the two models, we presented the results of
the fixed-effect model analyses. Otherwise, we presented the re-
sults of both analyses. The I2 statistic was presented as a measure
of the percentage of variation due to heterogeneity rather than
chance (Higgins 2003). The analyses were performed using the
intention-to-treat principle including all randomised participants
irrespective of follow-up. Drop-outs, withdrawals and non-com-
pliance were considered as treatment failures. Details are given in
’early stopping’ section.
From the data generated by each included randomised clinical
trial, risk ratio was calculated for categorical outcome data and
standardisedmean differences for continuous data alongwith their
95%CI. The results from comparable groups of trials were pooled
into statistical meta-analysis using RevMan (RevMan 2011). Het-
erogeneity between combined trials was tested using standard chi-
square test.Where statistical pooling was not possible, the findings
were summarised by listing and narrating.
Subgroup analysis and investigation of heterogeneity
We performed the following subgroup analyses:
- lower median dose of interferon compared to upper median dose
of interferon (Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis
3.4).
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We could not perform the below listed subgroup analyses either
because there were no sufficient data in the included trials or be-
cause the topic was not addressed.
- trials with low risk of bias compared to trials with high risk of
bias;
- trials with short follow-up (less than six months) compared to
trials with long follow-up (more than twelve months);
- pretreatment levels of ALT and/or AST;
- types of interferon administered;
- adult compared to paediatric patients;
- patients with coinfectionwith hepatitis C virus orHIV compared
to patients without coinfection;
- patients with alcohol problems compared to patients without
coinfection;
- patients with immunosuppressive drugs compared to patients
without coinfection;
- patients with liver transplantation compared to patients without
liver transplantation.
R E S U L T S
Description of studies
Results of the search
The search strategy identified 35 studies for consideration, out of
which six trials fulfilled the criteria for inclusion and were used for
our meta-analyses (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Six trials with 201 randomised participants provided data for anal-
ysis; 174 were males and 27 were women (Table 1). Five trials
compared interferon monotherapy versus no intervention con-
trol (Porres 1989; Rosina 1989; Rosina 1991; Farci 1994; Gaudin
1995). A total of 169 patients were included in these five trials;
92 in the intervention group and 77 in the no intervention group.
The baseline characteristics of the patient sample included in the
trials did not show any substantial differences between the groups
in the individual trials as well as across the trials. These trials had
methodological heterogeneity in terms of dosage regimen of in-
terferon alpha and duration of administration of interferon (re-
fer to Characteristics of included studies table). The duration of
treatment was one year in three trials, six months in one (Porres
1989), and three months in another trial (Rosina 1989). Out of
the five trials mentioned above, four trials (Porres 1989; Rosina
1989; Rosina 1991; Gaudin 1995) randomised patients to inter-
feron alpha versus no intervention in the control group. The fifth
trial (Farci 1994) had three groups; two interferon alpha interven-
tion groups and a control group with no treatment. The interferon
groups tested a lower dose (3 million units thrice a week) and a
higher dose (9million units thrice aweek).We analysed both treat-
ment regimens as a single group in a primary analysis (Analysis
2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4; Analysis 2.5) and as
separate groups in the analysis of different interferon dosages. The
remaining trial (Madejon 1994) compared a higher dose of inter-
feron alpha (18 million units thrice a week for 6months, 9 million
units thrice a week for 1 month, 6 million units tiw for 1 month,
3 million units thrice a week for 4 months) versus a lower dose (3
million units daily for 3 months then 1.5 million units daily for 9
months) of interferon alpha.We have included theMadejon 1994
trial in a subgroup analysis (Analysis 3.1; Analysis 3.2; Analysis
3.3; Analysis 3.4),
Excluded studies
Among the 29 excluded studies, two studies lacked a well-de-
scribed control group (Borghesio 1995; Di Marco 1996). The re-
mainder were not randomised clinical trials or addressed different
topics (Characteristics of excluded studies).
Risk of bias in included studies
The risk of bias domains were utilised to evaluate the individual
trial for risk of systematic error (Higgins 2011). The results are
summarised in Figure 2 and Figure 3. All the trials had high risk
of bias.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Figure 3. Methodological quality graph: review authors’ judgments about each methodological quality item
presented as percentages across all included studies.
Allocation
All of the included trials randomly allocated patients to compar-
ison groups. Four trials had computer-generated allocation se-
quence, and the process was regarded as adequate. In Porres 1989
and Rosina 1989, the authors did not give sufficient details re-
garding the method used and simply stated that the patients were
randomly allocated into two groups.
Regarding concealment of allocation, Farci 1994 was the only pos-
itive exception using computer-generated sealed envelopes. Even
this trial does not mention whether the envelopes were opaque or
not, or if they were consecutively numbered. None of the other
included trials mentioned a specific process of concealment. This
was regarded as lack of concealment.
Blinding
None of the included trials utilised blinding.
Incomplete outcome data
The included trials generally accounted for all the participants.
Outcome variables were identical, and outcomes data were com-
plete in nearly all the trials. The only exception to this was
Porres 1989, where the outcome variables were not clearly de-
fined. Nonetheless, we attempted to assess the results based on
established criteria for end of treatment response and sustained
virological response. These criteria provided a fair representation
of the trials. Wherever missing data were found, assessment was
based on an intention-to-treat principle, and a failure of treatment
was presumed. This happened mostly in case of a second biopsy,
which was not done in all the participants.
Selective reporting
All the included trials were considered free of selective report-
ing. Every trial reported on the predetermined outcomes for each
patient included, according to the trial report. We acknowledge,
however, that we did not have access to any of the trial protocols.
Other potential sources of bias
Baseline imbalance
The baseline characteristics of patients between experimental and
control groups were similar. The only possible exception was the
apparent disparity in the duration of disease between the two
groups in Madejon 1994 (62.6 ± 10.4 months in low dose inter-
feron versus 49.7 ± 9.8 in high dose group).
Early stopping
In Rosina 1991 interferon was discontinued permanently in five
patients. Reasons were ulcer at the injection site in one patient,
acute icteric hepatitis in another, and non-compliance in three.
Eight untreated patients were withdrawn from the control group
for noncompliance. In Farci 1994, one patient was lost to follow-
up in the control group. Madejon 1994: Drop outs and with-
drawals were seven; three from the low dose and four from the
high dose group. Reasons were return to active drug abuse (n =
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2), neuropsychiatric disorder (n = 2), thrombocytopoaenia (n =
2), and voluntary withdrawal (n = 1).Gaudin 1995: Therapy was
discontinued in two patients; one at four months because of in-
duction of hyperthyroidsm and the other at 11 months because
of committed suicide. There were no drop-outs or early stopping
in Porres 1989 and Rosina 1989.
Unit-of-analysis bias
There was a clearmethodological heterogeneity among the trials as
already alluded to earlier. In one trial (Farci 1994), multiple treat-
ment groups were employed. The groups were then redefined to
ensure simplified pair-wise comparison for a representative analy-
sis. This may have resulted in a potential unit-of-analysis bias for
the meta-analysis.
Effects of interventions
Interferon alpha versus no intervention
Mortality
One patient in the interferon alpha group was reported to have
died by suicide towards the end of the study period (Gaudin 1995).
No other trials reported any deaths during the treatment or follow-
up period (Analysis 1.1).
Failure of sustained virologic response
A total of 169 patients were included in five trials; 92 in the inter-
vention group and 77 in the no intervention group. There were
seven drop-outs in the treatment group and nine in the control
group. By intention to treat analysis, failure of sustained virological
response (SVR) at six months follow-up was observed in 82.6%
in patients on interferon alpha compared with 94.8% in controls
(RR 0.89, 95% CI 0.80 to 0.98, P = 0.02) (Analysis 2.2). I2 of
41% also indicated a more homogenous distribution among the
meta-analysed groups.
Interferon alpha administration led to failure of end of treatment
response in 67.4% of the patients compared with 92.2% in con-
trols based on clearance of HDV DNA (RR 0.76, 95% CI 0.66
to 0.87, P = 0.0001 by fixed-effect model, RR 0.71, 95% CI 0.43
to 1.16, not significant by random-effects model) (Analysis 2.1).
There was considerable heterogeneity in pooled results (I2 = 89%,
P < 0.00001).
Adverse events
All the trials included in the analysis reported on adverse events
related to administration of interferon alpha. We classified ad-
verse events into two groups, viz, (a) adverse events not requiring
any modification in interferon therapy (Table 2), and (b) adverse
events requiring modification or termination of treatment (Table
3). Among the first set of complications, nearly every patient ex-
perienced flu-like symptoms across the trials. Other commonly
reported adverse events included anorexia, nausea, weight loss,
alopaecia, leukopaenia, and thrombocytopaenia.
Quality of life
None of the trials reported on the quality of life.
Failure of sustained biochemical response
At six months follow-up, ALT was abnormal in 88.0% treated
patients versus 98.7% controls (RR 0.92, 95% CI 0.84 to 0.99,
P = 0.04) (Analysis 2.4). There was no significant heterogeneity
among the trials on these counts (end of treatment: I2 = 0%, P =
0.57, sustained biochemical response I2 = 0%, P = 0.41).
Failure of normalisation of ALT at the end of treatment was seen
in 65.2% patients treated with interferon alpha versus 98.7% in
the no intervention control group (RR 0.69, 95%CI 0.59 to 0.80,
P < 0.00001) (Analysis 2.3).
Failure of histological response
Assessment of histological response was restricted on a number of
accounts. Different trials were unable to repeat biopsies on all the
participants; this was especially true of untreated control group
participants. An assumption of no improvement in histology was
thus presumed in those with missing biopsy. Additionally, report-
ing of histological findings and grading of severity were performed
on different scales among the trials. We decided to assess histologi-
cal outcome as a dichotomous variable with improvement noticed
or no improvement noticed among participants of a trial. There
was no histological improvement in 72.8% patients treated with
interferon alpha compared with 84.4% in controls (RR 0.86, 95%
CI 0.74 to 1.00, P = 0.06) (Analysis 2.5). There was no hetero-
geneity among the trials (I2 0 %, P = 0.50).
Subgroup analysis
We searched the trials for data on patients with hepatitis C virus
and HIV co-infection, alcoholism, patients using immunosup-
pressive drugs, and liver transplanted patients in order to perform
subgroup analyses. However, none of the trials fulfilling the in-
clusion criteria of the review protocol provided specific details of
the individual patients in this regard, and these subgroup analyses
could not be performed. However, we performed the subgroup
analysis comparing high median dose of interferon alpha with low
dose. Data about improvement in the quality of life were also not
available.
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Interferon alpha high dose compared with interferon
alpha low dose
Two trials, comparing a higher cumulative dose regimen with a
lower dose regimen of interferon alpha, failed to achieve sustained
virologic response in 76.7% of the patients with higher dose com-
pared to 90% with the lower dose (RR 0.85, 95% CI 0.68 to
1.07), but this difference was not statistically significant (P = 0.16)
(Analysis 3.1; Analysis 3.2) (Farci 1994; Madejon 1994). There
was also no significant difference in biochemical response between
high dose and low dose interferon groups (Analysis 3.3; Analysis
3.4).
D I S C U S S I O N
Summary of main results
Chronic hepatitis D aggravates the natural course of hepatitis B
infection. It is difficult to treat hepatitis D. Interferon is the only
treatment for chronic hepatitis D. Randomised clinical trials based
on interferon therapy were conducted in late 1980s and early
1990s. These trials are few. The response evaluated was clearance
of HDV RNA (virological response), normalisation of ALT (bio-
chemical response), and histological improvement based on liver
biopsy. We found absence of significant sustained virological re-
sponse, improvement in ALT, and histological improvement in
our analysis. We observed, however, a potential effect of interferon
on end of treatment virological and biochemical responses. These
observations are hampered by the risk of significant errors (bias)
and the risk of random error (play of chance). We, therefore, tend
to agree with Hughes et al (Hughes 2011): interferon alpha, stan-
dard or pegylated, seems to be the only effective therapy available
so far for HDV, though it may not be an ideal treatment. This
therapy may not cure the infection in all patients, but it may po-
tentially benefit in some patients. Such potential effects come at a
price: increased risk of adverse events and of costs.
Interesting, although sustained virological response is not achieved
in all patients, biochemical response appears to correlate with im-
provement in liver histology. The beneficial effect lasts even be-
yond the termination of therapy. A 2 to 14 year follow-up study
of patients from Farci 1994 showed that high doses of interferon
alpha-2a (9 million units thrice a week) significantly improved the
long-term clinical outcome and survival of patients with chronic
hepatitis D, even though the majority had active cirrhosis before
the onset of therapy (Farci 2004). These patients had a sustained
decrease in HDV replication, leading to clearance of HDV RNA
and, eventually, hepatitis B virus (HBV) in some patients, as well
as a dramatic improvement in liver histology with respect to ac-
tivity grade and brosis stage. So, the clearance of serum HDV
RNA associated with loss of HBsAg may occur years after discon-
tinuation of treatment (Lau 1999). In patients, who do not clear
HDV RNA but do show biochemical and histological response,
interferon probably induces less pathogenic mutants (Ottobrelli
1991).
With the development of pegylated interferon, uncontrolled stud-
ies on hepatitis D have appeared in literature. Castelnau et al
showed an end of treatment virological response of 57% (8/14)
with pegylated interferon alpha 2b 1.5 microgram per kg and sus-
tained virological response of 43% (Castelnau 2006). However,
another study of 12 patients using the same dose showed a sus-
tained virological response of only 17% (Erhardt 2006). Negative
polymerase chain reaction (PCR) or decrease of more than three
logs in HDV RNA level at six months of intervention is correlated
with sustained virological response. In an international trial done
by Wedemeyer and colleagues (HIDIT-1), pegylated interferon
alpha 2a had a significant antiviral efficacy againstHDV,with 28%
achieving a sustained virological response (Wedemeyer 2011).
HBsAg is required for production of viral hepatitis D particles,
and active suppression of this antigen seems, therefore, a must.
Few trials have compared the effectiveness of combination of one
of the nucleoside analogues or ribavirin with standard or pegylated
interferon versus interferon alone. These combinations failed to
show advantage of using combination over interferon monother-
apy (Niro 2006). Available therapies do not effectively suppress
the surface antigenbut dohave some effect in reducing its level. For
example, lamivudine and famciclovir individually are ineffective
againstHDV (Yurdaydin 2002;Niro 2005a). Four randomised tri-
als comparing interferon monotherapy with lamivudine, adefovir
dipivoxil, or ribavirin combination with interferon failed to show
improvement in the virological and biochemical responses over in-
terferonmonotherapy (Gunsar 2005; Canbakan 2006; Yurdaydin
2008; Wedemeyer 2011). Inclusion of these more recent trials in
the analysis is beyond the scope of what was defined in the objec-
tives of the current review.
There is a need to develop new therapies effective directly against
HDV. There are few reports of clearance of HBsAg in up to 11%
of the patients of hepatitis B with one year of pegylated inter-
feron therapy.Thus, monitoring ofHBsAg levels along withHDV
RNA levels would be recommended in future trials to evaluate
response. Ideally treatment should be continued until the loss of
HBsAg. Monitoring HDV RNA levels could help in predicting
the response and adjusting the duration of therapy just as done for
hepatitis C (Lok 2007; EASL 2009; Ghany 2009) The HIDIT-
1 trial showed that combination of pegylated interferon with ade-
fovir dipivoxil was superior to interferon monotherapy in reduc-
ing HBsAg levels (Wedemeyer 2011). There is a need for ran-
domised trials comparing pegylated interferon monotherapy with
its combination with more powerful nucleos(t)ide analogues and
for longer duration. In the future, drugs directly acting on HDV
life cycle such as antisense oligonucleotides (Chen 1997), preny-
lation inhibitors (Bordier 2003), and HBV/HDV virus entry in-
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hibitors (Petersen 2008) would also have some role alone, or prob-
ably in combination with pegylated interferon.
Overall completeness and applicability of
evidence
From the available trials’ data we may conclude that interferon
alpha potentially seems effective in suppressing viral activity and
decreasing liver disease activity in some patients, but the inhibitory
effect is temporary, and improvement is not sustained in the ma-
jority of patients. From the limited data available, it is not possible
to find out any predictive factors or determinants of response. Due
to low sustained response, it seems difficult to accept this agent as
standard of care for hepatitis D. The possibility that pegylated in-
terferon might be more effective needs further evaluation in clini-
cal trials. The reason is that all included trials had high risk of bias
(systematic errors) and high risk of play of chance (random errors)
and we cannot exclude outcome measure reporting bias as well as
publication bias.
Quality of the evidence
Data from the available randomised trials were difficult to com-
pare due to the small number of trials and differences in the dose,
duration, and agents used in combination. In addition tomethod-
ological heterogeneity, only one subgroup analysis could be con-
ducted. All trials were unblinded, and several of them also showed
other bias risks. Allocation concealment was not observed or was
not clear. However, these trials were considered free from selective
reporting and incomplete outcome datawere adequately addressed
by most of the trials. Assessment was based on an intention-to-
treat principle. Possibility of publication bias cannot be excluded,
and the risk of bias in the included trials was high.
Potential biases in the review process
We did not limit our search to English language publications only.
However, the databases we searched contain less number of jour-
nals indexed from the developing world. We tried to retrieve the
unpublished data by going through the abstracts from liver meet-
ings. Data of an unpublished trial were generously provided by
their authors. However, during the process of writing the review,
the study got published (Wedemeyer 2011). This meta-analysis
is based on a small number of trials, with each trial comprising
a small sample size compounded by the differing dosage and du-
ration of interferon administration. These limitations carry over
into our analysis, and in our opinion, restricts definitive conclu-
sion regarding this treatment.
Agreements and disagreements with other
studies or reviews
Other reviews have also highlighted the limited efficacy of inter-
feron alpha against hepatitis D (Malaguarnera 1996; Farci 2003;
Niro 2005; Farci 2007; Wedemeyer 2010). They have mentioned
the individual studies and have drawn conclusions without per-
forming meta-analysis. There is one meta-analysis available which
has been done by Hadziyannis (Hadziyannis 1991). However, it is
based onbiochemical response, andused reduction inALT levels as
the primary outcomemeasure.While we did the systematic review
comparing the trials in clinically relevant outcome measures such
as mortality, virological, biochemical, and histological responses
at the end of treatment and the end of the follow-up period and
calculated the meta-analysis results. We also did subgroup analysis
comparing high dose with low dose of interferon.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Administration of interferon to patients with chronic hepatitis D
can neither be supported nor refuted. Interferonmay benefit some
patients through long-term remission. The patients run the risk
of adverse events and serious adverse events. Newer therapies are
needed.
Implications for research
Randomised clinical trials are needed to compare interferon alpha
versus placebo (or no placebo), pegylated interferon with standard
interferon, to determine duration of therapy, ie, 12 months versus
18 or 24 months, to document any improvement in response with
combination of newer, more powerful nucleoside or nucleotide
analogues, and to evaluate combination of pegylated interferon
with prenylation inhibitors or HBV/HDV virus entry inhibitors.
Other possible interventions ought to be assessed in chronic hep-
atitis D. A possible candidate could be a HBV/HDV virus entry
inhibitor. In the future, trials ought to be reported according to
the recommendations of CONSORT (http://www.consort-state-
ment.org/).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Porres 1989
Methods Randomised clinical trial.
Sample size: no justification.
Intention-to-treat: yes.
Interim analyses: no.
Participants Patients with chronic hepatitis D from Spain (n = 20).
Inclusion criteria: positive HDV-IgM antibody, biopsy proven chronic hepatitis with
intrahepatic delta antigen
Exclusion criteria: previous antiviral or steroid therapy, signs of active HBV infection,
ie, HBeAg or HBV DNA
Treatment and comparison groups similar at the start of study
Interventions Control: no treatment (n =10).
Experimental 1: interferon alfa-2c 10 million units/square meter twice a week (n =10).
Duration: six months.
Follow-up: 9 months post treatment.
Outcomes Loss of anti-HDV IgM.
Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.
Notes Three patients with positive anti-HIV (two in control and one in treatment group.
Subgroup analyses were not performed in the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “The patients were randomly allo-
cated into two groups.” Method not men-
tioned
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial design.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “ All the patients remained on the treat-
ment until the end of the treatment period”
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
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Rosina 1989
Methods Randomised clinical trial.
Sample size: no justification.
Intention-to-treat: yes.
Participants Patients with chronic hepatitis D (n =24) from Italy.
Inclusion criteria: positive HDV antibody, elevated ALT for one year, histological evi-
dence of chronic hepatitis and positive HDV antigen in liver Bx done within twomonths
Exclusion criteria: Not mentioned.
Interventions Control: no treatment (n =12).
Experimental 1: interferon alfa-2b 5 million units (MU) t.i.w. (n =12).
Duration: 3 months.
Follow-up: 9 months post treatment.
Liver biopsy at enrolment and end of post treatment follow-up
Outcomes Normalisation of ALT.
Improvement in liver histology.
Decrease in HDV RNA level.
Loss of HDV RNA.
Loss of HDV antigen in serum.
Notes Second liver biopsy was done in only 4/12 controls.
Two patients in the control group were negative for HDVRNA at the time of enrolment,
end of treatment, and end of follow-up and do not fulfil the criteria for response
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote“ the patients were matched for age
and sex, randomly assigned to a treated or
control group”. It is mentioned in the ab-
stract but not described in the “Materi-
als and Methods” section. In the compari-
son table, standard deviations for the age at
baseline were not mentioned, and baseline
ALT levels were not given
Allocation concealment (selection bias) High risk No.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial design.
Incomplete outcome data (attrition bias)
All outcomes
High risk Second liver biopsy was done in only 4/12
controls.
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
20Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rosina 1991
Methods Sample size: not calculated.
Intention-to-treat: yes.
Participants Patients with chronic hepatitis D (n =61) from Italy.
Inclusion criteria: positive HDV antibody, elevated ALT for one year, histological evi-
dence of chronic hepatitis or cirrhosis, and positive staining for HDAg on liver Bx done
within six months
Exclusion criteria were: previous interferon therapy, decompensated cirrhosis, concomi-
tant severe illness, proven drug abuse, prothrombin time greater than 4 s prolonged,
platelets < 100,000/cmm, WBC < 3000/cmm, granulocytes < 1500/cmm, creatinine >
1.7 mg/dl, anti-HIV antibodies
Interventions Control: no treatment (n = 30).
Experimental 1: interferon alfa-2b 5million units (MU) t.i.w. for 4months, 3MU thrice
a week for 8 months.Duration: 1 year (n = 31).
Follow-up: 1 year post treatment.
Liver biopsy at enrolment and second month of post treatment follow-up
Outcomes Normalisation of ALT.
Improvement in liver histology.
Decrease in HDAg in liver biopsy.
Loss of HDV RNA.
Notes Drop outs/withdrawals = 13; 5 from the treatment group and 8 from no treatment. Rea-
sons were ulcer at the injection site in1, acute icteric hepatitis in 1, and non-compliance
3 in the treatment group and 8 in the control group. Intention-to-treat analysis done.
However, authors preferred per protocol analysis for the histological improvement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote “Study patients were randomly as-
signed to the treatment or control group
(no placebo) using a computer-generated
randomisation code.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial design.
Incomplete outcome data (attrition bias)
All outcomes
High risk There were thirteen (out of 61 patients)
dropouts during study period. Quote “Of
these 61 patients, 48 (79%) have com-
pleted 24 months of the study”
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
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Farci 1994
Methods Sample size: no justification.
Generation of allocation schedule: by computer.
Allocation concealment: yes.
Intention-to-treat: yes.
Interim analyses: no.
Participants Patients with chronic hepatitis D (n = 42) from Italy.
Inclusion criteria: age 18 to 60, positive HDV antibody, serumHDV RNA documented
on three occasions in the last six months, elevated ALT for six months, histological
evidence of chronic hepatitis, positive test for intrahepatic delta antigen, no signs of
active HBV infection
Exclusion criteria were: antiviral therapy within six months, pregnancy, lactation, de-
compensated cirrhosis, clotting abnormalities precluding liver biopsy, hepatocellular car-
cinoma, WBC < 3000/cmm, platelets < 100,000/cmm
Interventions Control: no treatment (n =14).
Experimental 1: interferon alfa-2a 9 million units thrice a week (n =14)
Experimental 2:interferon alfa-2a 3 million units thrice a week (n =14).
Duration : 48 weeks.
Follow-up: 6 months post treatment.
Long term follow-up: mean 32 months (24 to 48).
Outcomes Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.
Notes One patient lost to follow-up in the control group. Intention to treat analysis was done
throughout. Experimental 1 and 2 groups were taken together and compared with the
control group. Control group did not get end of treatment biopsy. However, all groups
offered six months post treatment biopsy, and these data were used for analysis of histo-
logical improvement
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Unclear risk “Using computer-generated sealed en-
velopes, we randomly assigned patients...”
It does not mention whether the envelops
were opaque or not
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial design.
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Farci 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “All patients with the exception of
one in the control group were evaluated at
the end of six months of follow-up.”
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
Madejon 1994
Methods Sample size: calculated.
Generation of allocation schedule: by computer.
Allocation concealment: not used.
Intention-to-treat analysis: yes.
Interim analyses: no.
Participants Patients with chronic hepatitis D (n =32) from Spain. Inclusion criteria: positive HDV
antibody, presence of serum HDV RNA documented in the last six months, elevated
ALT for six months, histological evidence of chronic hepatitis or cirrhosis. Six patients
(18%) had anti-HCV and 2 (6%) anti-HIV antibodies. Exclusion criteria were: antiviral
or immunosuppressive therapy within one year, decompensated cirrhosis (Child B or C)
, concomitant severe illness, proven active drug abuse, prothrombin time less than 50%
of normal valve, platelets < 75,000/cmm
Interventions Experimental 1: interferon alfa-2a 18 million units (MU) thrice a week for 6 months,
9 MU thrice a week for 1 month, 6 MU t.i.w. for 1 month, 3 MU thrice a week for 4
months (n =16) .
Experimental 2: interferon alfa-2a 3 million units daily for 3 months then 1.5 MU daily
for 9 months (n =16).
Duration : 1 year.
Follow-up: 18 months post treatment.
Liver biopsy at enrolment and second month of post-treatment follow-up
Outcomes Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.
Notes Drop outs/withdrawals = 7; 3 from low dose and 4 from high dose. Reasons were: return
to active drug abuse (n =2), neuropsychiatric disorder (n =2), thrombocytopoenia (n =
2), and voluntary withdrawal (n =1). Intention to treat analysis was done throughout.
Histological improvement was less than 2 points
No end of treatment biopsy available. Liver biopsy was done after 18 months posttreat-
ment follow-up period
Risk of bias
Bias Authors’ judgement Support for judgement
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Madejon 1994 (Continued)
Random sequence generation (selection
bias)
Low risk Quote “ The patients were randomly allo-
cated into two groups by means of a com-
puter random-sample generation.”
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
High risk Unblinded trial design.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote “All but seven (three from group
I and four from group II) finished the
treatment period... All dropout patients
had persistently increased ALT values and
HDV RNA positivity when they left the
study.” Missing outcomes data balanced
across groups
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
Gaudin 1995
Methods Sample size: not calculated.
Randomisation: performed effectively.
Generation of allocation schedule: by computer-generated randomisation code.
Allocation concealment: not used.
Intention-to-treat: yes.
Interim analyses: no.
Participants Patients with chronic hepatitis D (n =22) from France.
Inclusion criteria: age 18 to 65, positive HDV antibody, serumHDV RNA documented
in the last six months, elevated ALT (> 1.5 times normal) on three occasions for six
months, histological evidence of chronic hepatitis, positive test for intrahepatic delta
antigen, no signs of active HBV infection
Exclusion criteria were: antiviral therapy within 24 months, pregnancy, lactation, de-
compensated cirrhosis, clotting abnormalities precluding liver biopsy, hepatocellular car-
cinoma, WBC < 3000/cmm, platelets < 100,000/cmm, alcoholism or other drug addic-
tion, or HIV positivity
Interventions Control: no treatment (n =11).
Experimental 1: interferon alfa-2a 5 million units/m2 body surface area thrice a week
for 4 months, then 3MU/m2 for 8 months (n =11).
Duration : 52 weeks.
Follow-up: 18 months post treatment.
Outcomes Loss of HDV RNA.
Normalisation of ALT.
Improvement in liver histology.
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Gaudin 1995 (Continued)
Notes Therapy was discontinued in two patients, one at 4 mo because of induction of hyper-
thyroidsm and other at 11 months because of death by suicide. Intention to treat analysis
was done throughout. Histological improvement was less than 2 points
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote, ” ... were randomly allocated to re-
ceive either no treatment or IFN-a using a
computer generated randomisation code
Allocation concealment (selection bias) Unclear risk Not mentioned.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not possible with the trial design
Incomplete outcome data (attrition bias)
All outcomes
Low risk Therapy was discontinued in two patients,
one at 4 months because of induction of
hyperthyroidsm and other at 11 months
because of death by suicide. Intention to
treat analysis was done throughout
Selective reporting (reporting bias) Low risk Outcome measures adequately reported.
t.i.w. = three times a week.
HDV = hepatitis D virus.
anti-HDV IgM = anti-hepatitis D virus antibody IgM.
HDAg = hepatitis D antigen.
ALT = alanine aminotransferase.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Battegay 1994 Not a randomised clinical trial.
Berk 1991 Not a randomised clinical trial.
Borghesio 1995 Lymphoblastoid IFN 10 MU t.i.w (n = 8) compared with 5 MU daily (n = 6). Both groups treated up to
ALT normalization plus 12 months. Basically same dose with two different regimens. No control group. Interm
results
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(Continued)
Buti 1989 Not a randomised clinical trial.
Canbakan 2006 Interferon monotherapy compared with interferon plus lamivudine. Though a randomised trial, the trial does
not fit within the prespecified comparisons of the review
Castelnau 2006 Not a randomised clinical trial.
Craxi 1990 Not a randomised clinical trial.
Deny 1994 Not a randomised clinical trial.
Di Bisceglie 1990 Not a randomised clinical trial.
Di Marco 1996 Not a randomised clinical trial. One year treatment compared with two year treatment. Two groups enrolled
sequentially; first one year treatment group and then two year treatment group. No control group. Low dose
interferon given to both groups
Erhardt 2006 Not a randomised clinical trial.
Farci 1989 Not a randomised clinical trial.
Gunsar 2005 Interferon monotherapy compared with interferon plus ribavirin. Though a randomised trial, the trial does not
fit within the prespecified comparisons of the review
Kaymakoglu 2005 Not a randomised clinical trial.
Lau 1993 Not a randomised clinical trial. Eleven patients, out of which five treated after one year of observation. Data
analysed together. HDV RNA not available. SVR not clear
Lau 1999 Not a randomised clinical trial. Follow-up of a single patient
Manesis 2007 Not a randomised clinical trial.
Marinucci 1991 Not a randomised clinical trial.
Marzano 1992 Not a randomised clinical trial.
Puoti 1998 Not a randomised clinical trial.
Rizzetto 1986 Not a randomised clinical trial.
Rumi 1995 A Not a randomised clinical trial.
Rumi 1995 B Not a randomised clinical trial.
Schneieder 1998 Not a randomised clinical trial.
Taillan 1988 Not a randomised clinical trial.
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(Continued)
Wedemeyer 2011 Pegylated interferonmonotherapy compared with pegylated interferon plus adefovir and adefovir monotherapy.
Though a randomised trial, the trial does not fit within the prespecified comparisons of the review
Wolters 2000 Not a randomised clinical trial.
Yurdaydin 2007 Not a randomised clinical trial.
Yurdaydin 2008 Interferon monotherapy compared with interferon plus lamivudine and adefovir monotherapy. Though a ran-
domised trial, the trial does not fit within the prespecified comparisons of the review
t.i.w. = three times a week.
SVR = sustained virological response.
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D A T A A N D A N A L Y S E S
Comparison 1. Mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Interferon alpha versus no
intervention
5 169 Risk Ratio (M-H, Random, 95% CI) 3.00 [0.14, 66.53]
Comparison 2. Interfeon alpha 2a versus no treatment for hepatitis D
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure of virological response:
end of treatment
5 169 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.66, 0.87]
2 Failure of virological response:
six months after completion of
treatment
5 169 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.80, 0.98]
3 Failure of biochemical response:
end of treatment
5 169 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.59, 0.80]
4 Failure of biochemical response:
six months after completion of
treatment
5 169 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.84, 0.99]
5 Failure of histological response 5 169 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.74, 1.00]
Comparison 3. Higher dose of standard interferon versus lower dose
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Failure of virological response:
end of treatment
2 60 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.59, 1.05]
2 Failure of virological response:
six months after completion of
treatment
2 60 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.68, 1.07]
3 Failure of biochemical response:
end of treatment
2 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.75, 1.33]
4 Failure of biochemical response:
Six months after completion of
treatment
2 60 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.84, 1.43]
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Analysis 1.1. Comparison 1 Mortality, Outcome 1 Interferon alpha versus no intervention.
Review: Interferon alpha for chronic hepatitis D
Comparison: 1 Mortality
Outcome: 1 Interferon alpha versus no intervention
Study or subgroup Interferon alpha
No
intervention
control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Farci 1994 0/28 0/14 Not estimable
Gaudin 1995 1/11 0/11 100.0 % 3.00 [ 0.14, 66.53 ]
Porres 1989 0/10 0/10 Not estimable
Rosina 1989 0/12 0/12 Not estimable
Rosina 1991 0/31 0/30 Not estimable
Total (95% CI) 92 77 100.0 % 3.00 [ 0.14, 66.53 ]
Total events: 1 (Interferon alpha), 0 (No intervention control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours interferon alpha Favours no intervention
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Analysis 2.1. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 1 Failure of
virological response: end of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 1 Failure of virological response: end of treatment
Study or subgroup Interferon alpha
No
treatment
(control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farci 1994 13/28 14/14 24.6 % 0.48 [ 0.32, 0.72 ]
Gaudin 1995 4/11 7/11 9.0 % 0.57 [ 0.23, 1.41 ]
Porres 1989 7/10 8/10 10.3 % 0.88 [ 0.53, 1.46 ]
Rosina 1989 8/12 12/12 16.1 % 0.68 [ 0.45, 1.02 ]
Rosina 1991 30/31 30/30 39.9 % 0.97 [ 0.89, 1.06 ]
Total (95% CI) 92 77 100.0 % 0.76 [ 0.66, 0.87 ]
Total events: 62 (Interferon alpha), 71 (No treatment (control))
Heterogeneity: Chi2 = 35.36, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 2 Failure of
virological response: six months after completion of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 2 Failure of virological response: six months after completion of treatment
Study or subgroup Interferon
No
treatment
(control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosina 1989 11/12 12/12 15.9 % 0.92 [ 0.74, 1.15 ]
Porres 1989 5/10 8/10 10.2 % 0.63 [ 0.31, 1.25 ]
Rosina 1991 30/31 30/30 39.3 % 0.97 [ 0.89, 1.06 ]
Farci 1994 20/28 13/14 22.0 % 0.77 [ 0.58, 1.01 ]
Gaudin 1995 10/11 10/11 12.7 % 1.00 [ 0.77, 1.30 ]
Total (95% CI) 92 77 100.0 % 0.89 [ 0.80, 0.98 ]
Total events: 76 (Interferon), 73 (No treatment (control))
Heterogeneity: Chi2 = 6.74, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 3 Failure of
biochemical response: end of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 3 Failure of biochemical response: end of treatment
Study or subgroup Interfeon
No
treatment
(control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rosina 1989 8/12 12/12 15.1 % 0.68 [ 0.45, 1.02 ]
Porres 1989 8/10 10/10 12.7 % 0.81 [ 0.57, 1.14 ]
Rosina 1991 23/31 30/30 37.4 % 0.75 [ 0.60, 0.92 ]
Farci 1994 14/28 13/14 20.9 % 0.54 [ 0.36, 0.80 ]
Gaudin 1995 7/11 11/11 13.9 % 0.65 [ 0.41, 1.03 ]
Total (95% CI) 92 77 100.0 % 0.69 [ 0.59, 0.80 ]
Total events: 60 (Interfeon), 76 (No treatment (control))
Heterogeneity: Chi2 = 2.93, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 4.93 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 4 Failure of
biochemical response: six months after completion of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 4 Failure of biochemical response: six months after completion of treatment
Study or subgroup Interferon
No
treatment
(control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porres 1989 10/10 10/10 12.7 % 1.00 [ 0.83, 1.20 ]
Rosina 1989 11/12 12/12 15.1 % 0.92 [ 0.74, 1.15 ]
Rosina 1991 30/31 30/30 37.4 % 0.97 [ 0.89, 1.06 ]
Farci 1994 20/28 13/14 20.9 % 0.77 [ 0.58, 1.01 ]
Gaudin 1995 10/11 11/11 13.9 % 0.91 [ 0.72, 1.17 ]
Total (95% CI) 92 77 100.0 % 0.92 [ 0.84, 0.99 ]
Total events: 81 (Interferon), 76 (No treatment (control))
Heterogeneity: Chi2 = 3.96, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Interfeon alpha 2a versus no treatment for hepatitis D, Outcome 5 Failure of
histological response.
Review: Interferon alpha for chronic hepatitis D
Comparison: 2 Interfeon alpha 2a versus no treatment for hepatitis D
Outcome: 5 Failure of histological response
Study or subgroup Interferon
No
treatment
(control) Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Porres 1989 10/10 10/10 14.9 % 1.00 [ 0.83, 1.20 ]
Rosina 1989 11/12 12/12 17.8 % 0.92 [ 0.74, 1.15 ]
Rosina 1991 20/31 25/30 36.1 % 0.77 [ 0.57, 1.05 ]
Farci 1994 21/28 12/14 22.7 % 0.88 [ 0.65, 1.18 ]
Gaudin 1995 5/11 6/11 8.5 % 0.83 [ 0.36, 1.94 ]
Total (95% CI) 92 77 100.0 % 0.86 [ 0.74, 1.00 ]
Total events: 67 (Interferon), 65 (No treatment (control))
Heterogeneity: Chi2 = 3.37, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours interferon alpha Favours control
34Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 1 Failure of
virological response: end of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 1 Failure of virological response: end of treatment
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farci 1994 4/14 9/14 37.5 % 0.44 [ 0.18, 1.11 ]
Madejon 1994 15/16 15/16 62.5 % 1.00 [ 0.84, 1.20 ]
Total (95% CI) 30 30 100.0 % 0.79 [ 0.59, 1.05 ]
Total events: 19 (High dose), 24 (Low dose)
Heterogeneity: Chi2 = 8.08, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 2 Failure of
virological response: six months after completion of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 2 Failure of virological response: six months after completion of treatment
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farci 1994 8/14 12/14 44.4 % 0.67 [ 0.40, 1.10 ]
Madejon 1994 15/16 15/16 55.6 % 1.00 [ 0.84, 1.20 ]
Total (95% CI) 30 30 100.0 % 0.85 [ 0.68, 1.07 ]
Total events: 23 (High dose), 27 (Low dose)
Heterogeneity: Chi2 = 4.00, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 3 Failure of
biochemical response: end of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 3 Failure of biochemical response: end of treatment
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farci 1994 12/14 9/14 39.1 % 1.33 [ 0.85, 2.08 ]
Madejon 1994 11/16 14/16 60.9 % 0.79 [ 0.54, 1.15 ]
Total (95% CI) 30 30 100.0 % 1.00 [ 0.75, 1.33 ]
Total events: 23 (High dose), 23 (Low dose)
Heterogeneity: Chi2 = 3.16, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Higher dose of standard interferon versus lower dose, Outcome 4 Failure of
biochemical response: Six months after completion of treatment.
Review: Interferon alpha for chronic hepatitis D
Comparison: 3 Higher dose of standard interferon versus lower dose
Outcome: 4 Failure of biochemical response: Six months after completion of treatment
Study or subgroup High dose Low dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Farci 1994 8/14 6/14 28.6 % 1.33 [ 0.63, 2.84 ]
Madejon 1994 15/16 15/16 71.4 % 1.00 [ 0.84, 1.20 ]
Total (95% CI) 30 30 100.0 % 1.10 [ 0.84, 1.43 ]
Total events: 23 (High dose), 21 (Low dose)
Heterogeneity: Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Male:female ratio
Study ID Male Female
Porres 1989 15 5
Rosina 1989 22 2
Rosina 1991 54 7
Farci 1994 35 7
Madejon 1994 26 6
Gaudin 1995 22 0
Total 174 27
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Table 2. Adverse events related to interferon therapy
Study ID Adverse events listed Percentage of patients
Porres 1989 Flu-like symptoms
Weight loss
Leukopoenia
Thrombocytopoenia
100
40
30
40
Rosina 1989 Flu-like symptoms
Transient hair loss
Herpes labialis
Granuloopoenia
100
33
25
67
Rosina 1991 Flu-like symptoms
Fatigue
Weight loss
Alopaecia
Nausea/Anorexia
Vomiting
Impaired consciousness
Rhinorrhea
100
100
100
17
35
6
3
3
Farci 1994 Flu-like symptoms
Asthenia
Alopaecia
Anemia
100
50
43
4
Madejon 1994 Asthenia
Anorexia
Fever
Weight loss
Arthralgias
Hair loss
Headache
Itching
56
50
47
47
41
38
38
12
Gaudin 1995 Flu-like symptoms
Leukopoenia
Thrombocytopoenia
Hyperthyroidism
Death (by suicide)
100
100
100
10
10
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Table 3. 2 Adverse events requiring dose modification or termination of interferon therapy
Study ID Events* Total number of participants %
Porres 1989 0 10 0
Rosina 1989 0 12 0
Rosina 1991 16 31 51.6
Farci 1994 2 28 7.1
Gaudin 1995 4 11 36.4
Madejon 1994 7 32 21.9
Total 29 124 23.4
Total number of participants are the patients who received interferon. Events represent number of participants experiencing adverse
events requiring dose modification or termination of therapy
A P P E N D I C E S
Appendix 1. Search strategies
Database Time Span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
May 2011 (*interferon* OR peg-ifn OR pegasus OR pegasys OR pegintron
OR ’viraferon peg’) AND ’hepatitis D’
Cochrane Central Register of Controlled
Trials (CENTRAL) in The Cochrane Li-
brary
Issue 2, 2011 #1 MeSH descriptor Interferon-alphaexplode all trees in MeSH
products
#2 interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg in All Fieldsin all products
#3 (#1 OR #2)
#4 MeSH descriptor Hepatitis Dexplode all trees in MeSH prod-
ucts
#5 hepatitis NEXT d in All Fieldsin all products
#6 (#4 OR #5)
#7 (#3 AND #6)
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(Continued)
MEDLINE (Ovid SP) 1950 to May 2011 1. exp Interferon-alpha/
2. (interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg).mp. [mp=title, original
title, abstract, name of substance word, subject heading word]
3. 1 or 2
4. exp Hepatitis D/
5. hepatitis d.mp. [mp=title, original title, abstract, name of sub-
stance word, subject heading word]
6. 4 or 5
7. 6 and 3
8. (random* or blind* or placebo* ormeta-analysis).mp. [mp=title,
original title, abstract, name of substance word, subject heading
word]
9. 8 and 7
EMBASE (Ovid SP) 1980 to May 2011 1. exp Alpha Interferon/
2. (interferon* or pegylated interferon or peginterferon or peg-ifn
or pegas*s or pegintron or viraferon peg).mp. [mp=title, abstract,
subject headings, heading word, drug trade name, original title,
device manufacturer, drug manufacturer name]
3. 1 or 2
4. exp Delta Agent Hepatitis/
5. hepatitis d.mp. [mp=title, abstract, subject headings, heading
word, drug trade name, original title, device manufacturer, drug
manufacturer name]
6. 4 or 5
7. 6 and 3
8. (random* or placebo* or blind* or meta-analysis).mp. [mp=
title, abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer name]
9. 8 and 7
Science Citation Index Expanded (http://
apps.isiknowledge.com)
1900 to May 2011 #5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-analysis)
#3 #2 AND #1
#2 TS=(hepatitis D)
#1 TS=(interferon* or pegylated interferon or peginterferon or
peg-ifn or pegas*s or pegintron or viraferon peg)
40Interferon alpha for chronic hepatitis D (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Zaigham Abbas drafted the protocol and review, performed the literature search, helped in data extraction, drafted the final review
incorporating comments of reviewers. Muhammad Arsalan Khan helped in literature search, performed data extraction, statistical
analysis, and co-drafted the final review. Mohammad Salih helped in literature search for writing the protocol. Wasim Jafri helped in
reviewing the studies and revising the final protocol and review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No source utilized, Not specified.
No internal Source of Funding Utilized
External sources
• No source utilized, Not specified.
No external sources of support utilized
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• Not all the subgroup analyses could be performed due to non-availability of data of individual patients.
• An extreme case-analyses was not conducted and dropouts were considered as failures in both groups.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antiviral Agents [adverse effects; ∗therapeutic use]; Hepatitis D, Chronic [drug therapy]; Interferon-alpha [adverse effects; ∗therapeutic
use]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Male
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